About Arcion: Leadership: Management

« Back to List

Kerrie L. Brady, B.Pharm, M.B.A., M.S., Chief Operating Officer

Kerrie L. Brady is an experienced international business development executive with a successful 25-year track record in working with both entrepreneurial ventures and established companies. Drawing on her functional expertise in business development, marketing, operations and regulatory affairs, she has forged strategic alliances to bring new products to market.

Prior to joining Arcion, Kerrie founded Traxion Therapeutics Inc., a newly established biotech company focused on the development of new drugs to treat intractable pain. Before Traxion, she was Vice President of Business Development at KMG Japan Inc, were she established partnerships between Japanese and Western companies. Her representative recent client base has included: Onyx Pharmaceuticals, Discovery Labs, Guilford, the Biotechnology Industry Organization, Arriva, Bentley, Angionics, ActivBioticis, CombinatoRx, Daiichi Sankyo and Mitsubishi Pharma.

Kerrie has held senior business development positions with the US biopharmaceutical companies EntreMed and Intracell. Prior to moving to the US, Kerrie spent 15 years in the Asia-Pacific region working with pharmaceutical companies, biotech companies and research organizations in the commercial development and marketing of new and emerging technologies. Kerrie began her career in the healthcare industry with regulatory and marketing positions at Rhone Poulenc.

Kerrie is a Board Member of the Technology Council of Maryland, member of the Licensing Executives Society of USA & Canada, Women In Bio, and the American Pain Society. She has a Bachelor of Pharmacy from the Victorian College of Pharmacy, an M.B.A. (Award of Distinction) from the University of Melbourne and a Masters in Science (Biopharmaceuticals) from the University of New South Wales.

"Arcion is lead by seasoned industry executives and scientific innovators."